Project CBD
FEBRUARY 28, 2023
The combined total from both channels — $58,293,034 — does not include CBD sales in licensed cannabis dispensaries or CBD products, such as vapes, tinctures, gummies, and other edibles sold online. (E-commerce Available at: [link] Accessed October 17, 2022. Accessed October 17, 2022. February 2, 2022.
Cannabis Law Report
JANUARY 24, 2022
DUBLIN–(BUSINESS WIRE)–The “North America Legal Cannabis Market Size, Share & Trends Analysis Report by Sources (Marijuana, Hemp), by Derivatives (CBD, THC), by End Use (Medical, Recreational), and Segment Forecasts, 2022-2028” report has been added to ResearchAndMarkets.com’s offering. from 2022 to 2028.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
MAY 10, 2022
11 May 2022. This is despite a limited number of high-quality clinical trials investigating the drug’s efficacy for this condition. Doctors are reaching for it as a catch-all tincture used to treat conditions for which there isn’t much evidence it’ll resolve, all at a “steeply” increasing rate. fphar-13-885655.
The Cannigma
AUGUST 14, 2022
Should you reach for a joint or a tincture? A 2022 rodent study found that cannabis significantly “increased functional coupling” in the RAS of male mice (but not female mice, oddly enough). It’s 3pm – the last stretch of the work day, and your mind is jumping around. As with all things in cannabis, it depends.
The Cannigma
JUNE 23, 2022
In the 2022 Oregon State University Study , the cannabinoid acids were found to bind to the spike proteins on the virus which are used to gain entry into the host or human cell. Products containing CBGA are available in many forms and are particularly popular as oral products including CBGA capsules and CBGA tinctures.
Cannabis Law Report
OCTOBER 29, 2021
(NYSE American: IGC) announces its financial results for the three months ended September 30, 2021, which is the second quarter of the Company’s 2022 fiscal year. During the six months ended September 30, 2021, the Company raised approximately $4.1 million of net proceeds from the issuance of equity stock.
The Cannigma
JANUARY 13, 2023
While migraines are a commonly reported condition by patients in cannabis studies, there is little clinical research on how cannabis can influence migraine pain. Russo concluded the evidence he examined “supports experimental protocols of cannabis usage in migraine treatment should go forward employing modern controlled clinical trials.”
Expert insights. Personalized for you.
144 
Let's personalize your content